James Krueger
Dermatology
Credentials: · ·
History
- 1982–1986
Doctor of Medicine
Research
Pathogenesis and therapy of psoriasis
Review · Nature · 2007 · Last of 3 authors · 1,385 citations
Review · Annual Review of Immunology · 2014 · Last of 3 authors · 1,327 citations
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells
Journal of Investigative Dermatology · 2008 · Last of 8 authors · 845 citations
136 papers · 18 as a resident
- ML
50 papers
44 papers · 16 as a fellow
- JF
29 papers
28 papers · 3 as a resident
27 papers
- KN
25 papers · 6 as a resident
24 papers · 8 as a resident
Grants
- 2016–2027
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success
National Center for Advancing Translational Sciences · UL1
PI · $17.5M · Rockefeller University
- 2001–2006
Therapeutic Immune Mechanisms of Daclizumab in Psoriasis
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $1.5M · Rockefeller University
- 1997–2005
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $4.3M · Rockefeller University
- 2001–2005
Therapeutic Immune Mechanisms of Anti-CD11a in Psoriasis
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $1.5M · Rockefeller University
Clinical trials
- 2017–2021
Safety and Efficacy of Secukinumab in Mild Psoriasis
Principal investigator · Completed · Phase 2
James G. Krueger, MD, PhD
- 2014–2018
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Principal investigator · Completed · Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
- 2013–2019
Principal investigator · Completed · Phase 2
Rockefeller University
- 2013–2015
Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis
Principal investigator · Completed · Phase 2
Rockefeller University